BLU-5937: Clinical Trials

3 trials of BLU-5937, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Active not recruiting 1, Completed 1, Recruiting 1

Follow BLU-5937: new trials by email Literature Review of BLU-5937 trials Research Report on BLU-5937

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
BLU-5937, Placebo - Refractory Chronic Cough
Phase 3RecruitingGlaxoSmithKline752025-11-212026-06-16
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
BLU-5937, Placebo - Cough, Refractory Chronic Cough
Phase 3Active not recruitingBellus Health Inc. - a GSK company9972022-12-052026-07-14
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
BLU-5937, Placebo - Cough, Refractory Chronic Cough
Phase 3CompletedBellus Health Inc. - a GSK company9572022-10-252026-07-14

Conditions studied

Chronic Cough (3)  ·  Cough (3)  ·  Respiration Disorders (2)  ·  Respiratory Tract Diseases (2)  ·  Signs and Symptoms, Respiratory (2)

Sponsors

Bellus Health Inc. - a GSK company (2)  ·  GlaxoSmithKline (1)

Countries

Canada (2)  ·  China (2)  ·  India (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Colombia (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Israel (1)  ·  Japan (1)

Results publications

PMID 39706278